title: In vitro immunomodulatory activity of interferon alpha on toll-like receptor 9 signaling pathway in chronic hepatitis B.
abstract: Interferon alpha (IFN-α) is registered for chronic hepatitis B (CHB) treatment. However, the antiviral mechanism of IFN-α and the biological function of many IFN-α responsive genes have not been fully elucidated. We investigated to determine the regulative effect of IFN-α on toll-like receptor (TLR) 9 signaling in peripheral blood mononuclear cells (PBMCs) from CHB patients in vitro. We examined the changes of expression and function of TLR9 signaling pathway in the PBMCs with different treatment methods and investigated the synergism of IFN-α and TLR9 ligand on antiviral cytokine secretions in vitro. The data showed that, for the TLR9 signaling pathway, IFN-α not only augmented the expressions of TLR9 signal transduction molecules but also activated the TLR9 signal function. This study has clearly demonstrated that the TLR9 ligand could stimulate PBMCs that have been pretreated with IFN-α. Furthermore, the quantity of antiviral cytokines secreted by the pretreated PBMCs was greater than those without pretreatment. The interaction between IFN-α and TLR9 ligand appears to be synergistic. Data revealed IFN-α could influence TLR9 signaling transduction and synergistically improve the immune efficacy of TLR9 ligand against CHB. The present study suggests a potential novel mechanism for the antiviral activity against hepatitis B virus and a new individualized antiviral strategy.
authors.affiliation: 1 Department of Infectious Diseases, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University , Xi'an, P.R. China .
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Ying-Ren
authors.initials: YR
authors.lastname: Zhao
authors.forename: Hong-Li
authors.initials: HL
authors.lastname: Liu
authors.forename: Xiao-Hua
authors.initials: XH
authors.lastname: Ma
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D016207:Cytokines / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D006515:Hepatitis B virus / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D050839:Interferon Regulatory Factor-7 / Q000235:genetics / Q000378:metabolism; D016898:Interferon-alpha / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008024:Ligands; D008297:Male; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D012333:RNA, Messenger; D015398:Signal Transduction / Q000187:drug effects*; D048029:TNF Receptor-Associated Factor 6 / Q000235:genetics / Q000378:metabolism; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000378:metabolism* / Q000819:agonists; D055815:Young Adult
chemical_list: C526902:CpG ODN 2216; D016207:Cytokines; D007155:Immunologic Factors; D050839:Interferon Regulatory Factor-7; D016898:Interferon-alpha; D008024:Ligands; D053594:Myeloid Differentiation Factor 88; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D048029:TNF Receptor-Associated Factor 6; D051217:Toll-Like Receptor 9